Magnolol / TGF-β Cancer Research Results

MAG, Magnolol: Click to Expand ⟱
Features:
Lignan found in bark of some magnolia species.
Magnolol (MAG) — a bioactive biphenolic compound from Magnolia officinalis
derived from the bark (roots and branches) of Magnolia species such as M. officinalis, M. obovata, and M. grandiflora
The two main bioactive compounds isolated from these plants are MAG (5,5ʹ-diallyl-2,2ʹ-dihydroxybiphenyl) and Honokiol (3,5ʹ-diallyl-4,2ʹ-dihydroxybiphenyl) (Fig. 1) which are phenolic regioisomers.
In the bark extracts of Magnolia plants, the composition of MAG ranges from 1 to 10%, while Honokiol comprises 1 to 5%
Magnolol is a biphenolic neolignan isolated from the bark of Magnolia officinalis. It is structurally related to honokiol and is studied for anti-inflammatory, antioxidant, antimicrobial, and neuroactive effects. In preclinical oncology models, magnolol is reported to modulate NF-κB, STAT3, PI3K/AKT, MAPK, Wnt/β-catenin, and redox pathways, with downstream effects on cell-cycle arrest, apoptosis, invasion/EMT, and angiogenesis. Oral bioavailability is limited and many cytotoxic concentrations reported in vitro are in the tens of µM range, often above typical systemic levels from standard supplementation.

major pathways and molecular targets involved in magnolol’s anticancer actions:
-Apoptosis: ↑ Bax, ↓ Bcl-2, ↑ cytochrome c, ↑ caspase-9, ↑ caspase-3
-Arrests cell cycle at G0/G1 or G2/M phase:↓ Cyclin D1, CDK4, CDK6, Cyclin B1, CDK1
-Inhibits NF-κB activation: ↓ IκBα, COX-2, TNF-α
-Inhibits PI3K, Akt, and mTOR phosphorylation
-Suppresses angiogenesis: ↓ Bcl-XL, Mcl-1, VEGF, cyclin D1
-Inhibits β-catenin nuclear translocation
-increase ROS production in tumor cells → triggers mitochondrial apoptosis
-Magnolol activates Nrf2 in normal cells → upregulates HO-1, NQO1: Protects normal tissue from oxidative stress during chemotherapy or inflammation.

Most in-vitro IC50 values fall in the 10–100 µM range, often above typical systemic exposure.

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 NF-κB inflammatory / survival transcription NF-κB ↓; COX-2, cytokines, Bcl-2 family ↓ (reported) Inflammation tone ↓ R, G Anti-inflammatory + anti-survival transcription One of the most consistently reported mechanisms in both inflammatory and tumor models.
2 STAT3 signaling STAT3 phosphorylation ↓ (reported) ↔ R, G Oncogenic transcription suppression Reported in several cancer cell systems; contributes to reduced proliferation and survival signaling.
3 PI3K → AKT → mTOR pathway PI3K/AKT signaling ↓ (model-dependent) ↔ R, G Growth/survival modulation Frequently described as downstream of inflammatory pathway suppression; context-dependent strength.
4 Nrf2 / ARE antioxidant response Modulation context-dependent; may decrease oxidative stress or alter redox tone Nrf2 ↑; HO-1 ↑; GSH ↑ (cytoprotective) R, G Redox regulation Magnolol activates Nrf2 in non-malignant oxidative stress models; tumor direction varies and may influence therapy sensitivity.
5 MAPK pathways (ERK / JNK / p38) MAPK modulation (stress activation or ERK suppression; context-dependent) ↔ P, R, G Signal reprogramming JNK/p38 activation and ERK modulation reported variably depending on cell type and dose.
6 Cell-cycle arrest (G0/G1 or G2/M) Cell-cycle arrest ↑ (reported) ↔ G Cytostasis Associated with Cyclin D1/CDK modulation and checkpoint protein regulation.
7 Intrinsic apoptosis (mitochondrial pathway) Apoptosis ↑; caspases ↑; Bax/Bcl-2 ratio ↑ (reported) ↔ (generally less activation) G Cell death execution Often downstream of survival pathway inhibition and ROS signaling shifts.
8 ROS / redox modulation ROS ↑ in some tumor models; antioxidant effects in non-tumor systems Oxidative stress ↓ in inflammatory models P, R, G Context-dependent redox modulation Biphasic redox behavior similar to other polyphenols; not a universally tumor-selective pro-oxidant.
9 Wnt/β-catenin signaling β-catenin signaling ↓ (reported) ↔ G Proliferation/invasion modulation Reported particularly in colorectal and hepatocellular carcinoma models; keep model-qualified.
10 Invasion / metastasis (MMPs / EMT) MMP2/MMP9 ↓; EMT markers ↓; migration ↓ (reported) ↔ G Anti-invasive phenotype Often secondary to NF-κB/STAT3 pathway suppression.
11 Bioavailability constraint Limited oral bioavailability; rapid metabolism — — Translation constraint Plasma levels after oral dosing are typically lower than many in-vitro cytotoxic concentrations.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid signaling/redox interactions)
  • R: 30 min–3 hr (acute transcription and stress-response signaling shifts)
  • G: >3 hr (gene-regulatory adaptation and phenotype outcomes)
TGF-β, transforming growth factor-beta: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-CS TCGA
Type:
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses.
Anti-inflammatory cytokine.
In normal tissues, TGF-β plays an essential role in cell cycle regulation, immune function, and tissue remodeling.
- In early carcinogenesis, TGF-β typically acts as a tumor suppressor by inhibiting cell proliferation and inducing apoptosis.

In advanced cancers, cells frequently become resistant to the growth-inhibitory effects of TGF-β.
- TGF-β then switches roles and promotes tumor progression by stimulating epithelial-to-mesenchymal transition (EMT), cell invasion, metastasis, and immune evasion.

Non-canonical (Smad-independent) pathways, such as MAPK, PI3K/Akt, and Rho signaling, also contribute to TGF-β-mediated responses.

Elevated levels of TGF-β have been detected in many advanced-stage cancers, including breast, lung, colorectal, pancreatic, and prostate cancers.
 - The switch from a tumor-suppressive to a tumor-promoting role is often associated with increased TGF-β production and activation in the tumor microenvironment.

High TGF-β expression or signaling activity is frequently correlated with aggressive disease features, resistance to therapy, increased metastasis, and poorer overall survival in many cancer types.
Scientific Papers found: Click to Expand⟱
4520- MAG,    Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
- vitro+vivo, PC, PANC1
Vim↓, E-cadherin↑, EMT↓, N-cadherin↓, p‑SMAD2↓, p‑SMAD3↓, TumCP↓, TumCMig↓, TumCI↓, TGF-β↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   N-cadherin↓, 1,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,   Vim↓, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TGF-β, transforming growth factor-beta
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:121  Target#:304  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page